I work at ValueFirst Digital Media Private Ltd. I am a Product Marketer in the Surbo Team. Surbo is Chatbot Generator Platform owned by Value First. ...Full Bio
I work at ValueFirst Digital Media Private Ltd. I am a Product Marketer in the Surbo Team. Surbo is Chatbot Generator Platform owned by Value First.
Success story of Haptik
500 days ago
Who is afraid of automation?
500 days ago
What's happening in AI, Blockchain & IoT
501 days ago
3 million at risk from the rise of robots
501 days ago
Health Entrepreneurs are using big data in an innovative way
If you look at it closely, you will see that in some ways Martine Rothblatt, the chairwoman and founder of United Therapeutics and James Park, CEO and co-founder of Fitbit are infact unusual entrepreneurs and healthcare leaders. Both were outsiders to the industry and neither of them were well versed with the regulatory arts of American Healthcare.
However both of them are natural inventors. Park had the vision of capturing gaming meets exercise magic of the famous Wii, while Rothblatt aimed to solve the issue of her daughter's pulmonary hypertension. Fast forward several years, and they have both moved well beyond their original objectives and continue to push the envelope in the healthcare industry. Using Fitbit, Park is partnering with a host of companies and his wearable gadget company is increasingly partnering with medical device companies, insurers and employers in order to motivate and engage people in a way that helps them improve their health. Rothblatt on the other hand after having found a drug to keep her daughter alive is now focusing on transplantable organs.
It's important to keep in mind that all this vision revolves around data. Speaking at an event, Park said that with Fitbit, he is not aiming to directly monetize data and sell it. He also noted that lot of regulations stand in his way.
Rothblatt explained that her company is betting big on genetic data and the potential it has to better understand the effectiveness of drugs. Participants at their clinical trials now have their genomes sequenced and researchers at their company plan to correlate patient data with the genomic sequenced data.
Rothblatt highlighted that they can cut down costs dramatically. They can help cut down the waste of somebody trying a medicine just because it was tried on average statistics over a large population. Instead, they should be able to precisely target medicines for a very precise genomic sequence.